Raj Kannan - 18 Mar 2022 Form 4 Insider Report for AERIE PHARMACEUTICALS INC

Role: Chief Executive Officer, Director
Signature: /s/ John LaRocca, Attorney-In-Fact for Raj Kannan
Issuer symbol: N/A
Transactions as of: 18 Mar 2022
Net transactions value: $0
Form type: 4
Filing time: 22 Mar 2022, 20:26:13 UTC
Previous filing: 22 Dec 2021
Next filing: 21 Nov 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AERI	Stock Option (right to buy)	Award	$0	+197,239		$0.000000	197,239	18 Mar 2022	Common Stock	197,239	$8.80	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This Option was granted under the Aerie Pharmaceuticals, Inc. Amended and Restated Inducement Award Plan and is scheduled to vest, subject to the reporting person's continued employment with the issuer through the applicable vesting date, as to 25% of the underlying shares on March 18, 2023 and as to the remaining underlying shares in substantially equal installments on each of the subsequent 36 monthly anniversaries of March 18, 2023.

Content

This Option was granted under the Aerie Pharmaceuticals, Inc. Amended and Restated Inducement Award Plan and is scheduled to vest, subject to the reporting person's continued employment with the issuer through the applicable vesting date, as to 25% of the underlying shares on March 18, 2023 and as to the remaining underlying shares in substantially equal installments on each of the subsequent 36 monthly anniversaries of March 18, 2023.